Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes
J. Romine(Bristol-Myers Squibb (United States)), Lawrence B. Snyder(Arvinas (United States)), Xiaohua Huang(City Of Hope National Medical Center), Nicholas A. Meanwell(Mario Negri Institute for Pharmacological Research), Donald R. O’Boyle(Bristol-Myers Squibb (United States)), John E. Leet(Franklin University), Denis R. St. Laurent(Bristol-Myers Squibb (United States)), Peter T. Nower, Jin-Hua Sun(University of Science and Technology of China), Michael H. Serrano‐Wu(Broad Institute), Min Gao(Shandong First Medical University), Fukang Yang(Bristol-Myers Squibb (United States)), Julie A. Lemm(Bristol-Myers Squibb (United States)), Milind Deshpande(Achillion Pharmaceuticals (United States)), Scott Martin(Bristol-Myers Squibb (United States))
Cited by 86
Related Papers
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
|Nature|2010|940
Highly Active and Selective Catalysts for the Formation of α-Aryl Ketones
|Journal of the American Chemical Society|2000|517
Applications of fluorine-containing amino acids for drug design
|European Journal of Medicinal Chemistry|2019|238
Identification of Hepatitis C Virus NS5A Inhibitors
|Journal of Virology|2009|196
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)
|Antimicrobial Agents and Chemotherapy|2012|186